Matching articles for "28"

Screening Mammography for Women 40-49 Years Old

   
The Medical Letter on Drugs and Therapeutics • December 14, 2009;  (Issue 1327)
Conflicting recommendations on when to screen for breast cancer are problematic for healthcare providers. The recent recommendation by the US Preventive Services Task Force (USPSTF) against routine screening...
Conflicting recommendations on when to screen for breast cancer are problematic for healthcare providers. The recent recommendation by the US Preventive Services Task Force (USPSTF) against routine screening mammography for women 40-49 years old conflicts with recommendations made by other organizations such as the American Cancer Society and earlier recommendations made by the USPSTF in 2002.

Click here to view the free full article.
Med Lett Drugs Ther. 2009 Dec 14;51(1327):97-8 | Show Full IntroductionHide Full Introduction

Rapid-Acting Insulin Analogues

   
The Medical Letter on Drugs and Therapeutics • December 14, 2009;  (Issue 1327)
Three rapid-acting insulin analogs are currently available: insulin lispro, insulin aspart and insulin glulisine. 1-3 All three are approved for use in both type 1 and type 2 diabetes, either by subcutaneous...
Three rapid-acting insulin analogs are currently available: insulin lispro, insulin aspart and insulin glulisine. 1-3 All three are approved for use in both type 1 and type 2 diabetes, either by subcutaneous injection, insulin pump or intravenous administration. All three cost more than regular insulin.
Med Lett Drugs Ther. 2009 Dec 14;51(1327):98 | Show Full IntroductionHide Full Introduction

Bone Morphogenetic Protein (Infuse Bone Graft)

   
The Medical Letter on Drugs and Therapeutics • December 14, 2009;  (Issue 1327)
Harvesting of autogenous bone, most commonly from the iliac crest, for use as the interbody graft in spinal fusion procedures has been standard practice, but is associated with a high rate of morbidity,...
Harvesting of autogenous bone, most commonly from the iliac crest, for use as the interbody graft in spinal fusion procedures has been standard practice, but is associated with a high rate of morbidity, including graft site pain, infection, fracture, bleeding and damage to the femoral nerve. Use of recombinant human bone morphogenetic protein (rhBMP-2; Infuse Bone Graft - Medtronic) was first approved by the FDA in 2002 for single-level anterior lumbar spinal fusion in adults with degenerative disc disease who had not responded to at least 6 months of nonoperative treatment. Now it has also been approved for treatment of open tibial fractures and for use in oral and maxillofacial bone grafting procedures.
Med Lett Drugs Ther. 2009 Dec 14;51(1327):99-100 | Show Full IntroductionHide Full Introduction

Drugs Past Their Expiration Date

   
The Medical Letter on Drugs and Therapeutics • December 14, 2009;  (Issue 1327)
Healthcare providers are often asked if patients can use drugs after their expiration date. Pharmaceutical companies, because of legal restrictions and liability concerns, will not sanction such use and might...
Healthcare providers are often asked if patients can use drugs after their expiration date. Pharmaceutical companies, because of legal restrictions and liability concerns, will not sanction such use and might not even comment on the safety or effectiveness of using their products beyond the date on the label. Since the last Medical Letter publication on this subject, more data have become available.
Med Lett Drugs Ther. 2009 Dec 14;51(1327):100-1 | Show Full IntroductionHide Full Introduction

Ophthalmic Besifloxacin (Besivance)

   
The Medical Letter on Drugs and Therapeutics • December 14, 2009;  (Issue 1327)
The FDA has approved the fluoroquinolone besifloxacin 0.6% ophthalmic suspension (Besivance - Bausch & Lomb) for treatment of bacterial conjunctivitis caused by susceptible bacteria. According to the...
The FDA has approved the fluoroquinolone besifloxacin 0.6% ophthalmic suspension (Besivance - Bausch & Lomb) for treatment of bacterial conjunctivitis caused by susceptible bacteria. According to the manufacturer, this product was developed specifically for ophthalmic use in a specialized vehicle designed to prolong contact time on the ocular surface. Besifloxacin is not available for systemic use.
Med Lett Drugs Ther. 2009 Dec 14;51(1327):101-3 | Show Full IntroductionHide Full Introduction

Mercury in Fish

   
The Medical Letter on Drugs and Therapeutics • December 14, 2009;  (Issue 1327)
Recent news articles about mercury in fish may lead some patients to seek more information from their healthcare providers. For most Americans, seafood is the major source of exposure to mercury. The mercury in...
Recent news articles about mercury in fish may lead some patients to seek more information from their healthcare providers. For most Americans, seafood is the major source of exposure to mercury. The mercury in seafood is in the form of methylmercury, a potential neurotoxin formed by the organification of elemental mercury by marine microorganisms like plankton, which are then consumed by aquatic animals and concentrated up the food chain.
Med Lett Drugs Ther. 2009 Dec 14;51(1327):103-4 | Show Full IntroductionHide Full Introduction

A Human Papillomavirus Vaccine

   
The Medical Letter on Drugs and Therapeutics • August 14, 2006;  (Issue 1241)
A recombinant quadrivalent human-papillomavirus-like particle vaccine, Gardasil (Merck), has been approved by the FDA for use in girls and women 9-26 years old to prevent diseases associated with infection with...
A recombinant quadrivalent human-papillomavirus-like particle vaccine, Gardasil (Merck), has been approved by the FDA for use in girls and women 9-26 years old to prevent diseases associated with infection with human papillomavirus (HPV) types 6, 11, 16, and 18, including genital warts, precancerous cervical, vaginal or vulvar lesions, and cervical cancer.
Med Lett Drugs Ther. 2006 Aug 14;48(1241):65-6 | Show Full IntroductionHide Full Introduction

Varenicline (Chantix) for Tobacco Dependence

   
The Medical Letter on Drugs and Therapeutics • August 14, 2006;  (Issue 1241)
Varenicline tartrate (Chantix - Pfizer) is now available for oral treatment of tobacco dependence. Some other drugs for this indication are listed in this...
Varenicline tartrate (Chantix - Pfizer) is now available for oral treatment of tobacco dependence. Some other drugs for this indication are listed in this article.
Med Lett Drugs Ther. 2006 Aug 14;48(1241):66-8 | Show Full IntroductionHide Full Introduction

Intravenous Ibandronate (Boniva)

   
The Medical Letter on Drugs and Therapeutics • August 14, 2006;  (Issue 1241)
Ibandronate (Boniva - Roche) is the first bisphosphonate approved by the FDA for intravenous (IV) treatment of osteoporosis in postmenopausal women. It is given as a bolus injection once every 3 months....
Ibandronate (Boniva - Roche) is the first bisphosphonate approved by the FDA for intravenous (IV) treatment of osteoporosis in postmenopausal women. It is given as a bolus injection once every 3 months. Ibandronate is also available as an oral once-a-month 150-mg tablet and as a daily 2.5-mg tablet.
Med Lett Drugs Ther. 2006 Aug 14;48(1241):68-9 | Show Full IntroductionHide Full Introduction

VariZIG for Prophylaxis After Exposure to Varicella

   
The Medical Letter on Drugs and Therapeutics • August 14, 2006;  (Issue 1241)
The US manufacturer of varicella zoster immune globulin (VZIG; Massachusetts Public Health Biologic Laboratories, Boston, MA) recently discontinued its production. A Canadian formulation, VariZIG (Varicella...
The US manufacturer of varicella zoster immune globulin (VZIG; Massachusetts Public Health Biologic Laboratories, Boston, MA) recently discontinued its production. A Canadian formulation, VariZIG (Varicella Zoster Immune Globulin [Human] - Cangene Corporation, Winnipeg) is now available in the US under an investigational new drug application expanded access protocol.
Med Lett Drugs Ther. 2006 Aug 14;48(1241):69-70 | Show Full IntroductionHide Full Introduction

Automated External Defibrillators

   
The Medical Letter on Drugs and Therapeutics • August 14, 2006;  (Issue 1241)
Sudden cardiac arrest has a survival rate of about 6% without immediate defibrillation. Automated external defibrillators (AEDs) can be found in many public locations such as shopping malls, office buildings...
Sudden cardiac arrest has a survival rate of about 6% without immediate defibrillation. Automated external defibrillators (AEDs) can be found in many public locations such as shopping malls, office buildings and schools. Some patients may ask their physicians whether they should purchase an AED for personal use. One device has been FDA-approved for sale over the counter (HeartStart Home Defibrillator - Philips). Purchase of all other AEDs for public places or home use requires authorization from a physician.
Med Lett Drugs Ther. 2006 Aug 14;48(1241):71-2 | Show Full IntroductionHide Full Introduction